Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:IMTE 10 November 2025

IMTE Stock Today: Nasdaq Delisting Clock Hits Nov. 10—Shares Trade as Hearing Stay Appears in Effect

IMTE Stock Today: Nasdaq Delisting Clock Hits Nov. 10—Shares Trade as Hearing Stay Appears in Effect

Integrated Media Technology Limited avoided a Nasdaq suspension at the open on Nov. 10, 2025, after failing to file its FY2024 Form 20-F on time. Shares traded heavily, suggesting the company requested a hearing, triggering an automatic 15-day stay. IMTE disclosed the delisting determination on Oct. 31 but has not confirmed the exact timing of its hearing request.
10 November 2025
··

Stock Market Today

  • Ocugen's Gene Therapy Pipeline Eyes Major 2026-2027 Milestones with Retinal Programs
    March 20, 2026, 9:35 AM EDT. Ocugen (OCGN) is set for a pivotal 2026-2027 with three retinal gene therapy candidates targeting retinitis pigmentosa, Stargardt disease, and geographic atrophy. The lead candidate, OCU400, has completed Phase III enrollment and aims for a rolling biologics license application by Q3 2026 and top-line data in Q1 2027. OCU400 uses a gene-agnostic modifier therapy to treat multiple mutations with one injection. Meanwhile, OCU410ST for Stargardt disease is in a Phase II/III study, with interim data expected in Q3 2026 and FDA filing planned for H1 2027. Both programs fill high unmet medical needs with no approved treatments. Regulatory applications and data readouts heavily influence OCGN's near-term stock catalysts, making timeline execution critical for investors.
Go toTop